Literature DB >> 19903768

Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer.

Joelle Hillion1, Lisa J Wood, Mita Mukherjee, Raka Bhattacharya, Francescopaolo Di Cello, Jeanne Kowalski, Ossama Elbahloul, Jodi Segal, John Poirier, Charles M Rudin, Surajit Dhara, Amy Belton, Biju Joseph, Stanley Zucker, Linda M S Resar.   

Abstract

Although lung cancer is the leading cause of cancer death worldwide, the precise molecular mechanisms that give rise to lung cancer are incompletely understood. Here, we show that HMGA1 is an important oncogene that drives transformation in undifferentiated, large-cell carcinoma. First, we show that the HMGA1 gene is overexpressed in lung cancer cell lines and primary human lung tumors. Forced overexpression of HMGA1 induces a transformed phenotype with anchorage-independent cell growth in cultured lung cells derived from normal tissue. Conversely, inhibiting HMGA1 expression blocks anchorage-independent cell growth in the H1299 metastatic, undifferentiated, large-cell human lung carcinoma cells. We also show that the matrix metalloproteinase-2 (MMP-2) gene is a downstream target upregulated by HMGA1 in large-cell carcinoma cells. In chromatin immunoprecipitation experiments, HMGA1 binds directly to the MMP-2 promoter in vivo in large-cell lung cancer cells, but not in squamous cell carcinoma cells. In large-cell carcinoma cell lines, there is a significant, positive correlation between HMGA1 and MMP-2 mRNA. Moreover, interfering with MMP-2 expression blocks anchorage-independent cell growth in H1299 large-cell carcinoma cells, indicating that the HMGA1-MMP-2 pathway is required for this transformation phenotype in these cells. Blocking MMP-2 expression also inhibits migration and invasion in the H1299 large-cell carcinoma cells. Our findings suggest an important role for MMP-2 in transformation mediated by HMGA1 in large-cell, undifferentiated lung carcinoma and support the development of strategies to target this pathway in selected tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903768      PMCID: PMC3069640          DOI: 10.1158/1541-7786.MCR-08-0336

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  47 in total

1.  HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma.

Authors:  Siong-Seng Liau; Amarsanaa Jazag; Edward E Whang
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

2.  CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.

Authors:  Ido Paz-Priel; Dong Hong Cai; Dehua Wang; Jeanne Kowalski; Amanda Blackford; Huaitian Liu; Caroline A Heckman; Adrian F Gombart; H Phillip Koeffler; Linda M Boxer; Alan D Friedman
Journal:  Mol Cancer Res       Date:  2005-10       Impact factor: 5.852

3.  Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.

Authors:  B Passlick; W Sienel; R Seen-Hibler; W Wöckel; O Thetter; W Mutschler; K Pantel
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

4.  Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas.

Authors:  Monica Fedele; Francesca Pentimalli; Gustavo Baldassarre; Sabrina Battista; Andres J P Klein-Szanto; Lawrence Kenyon; Rosa Visone; Ivana De Martino; Andrea Ciarmiello; Claudio Arra; Giuseppe Viglietto; Carlo M Croce; Alfredo Fusco
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

5.  HMG-I/Y, a new c-Myc target gene and potential oncogene.

Authors:  L J Wood; M Mukherjee; C E Dolde; Y Xu; J F Maher; T E Bunton; J B Williams; L M Resar
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

6.  The oncogenic properties of the HMG-I gene family.

Authors:  L J Wood; J F Maher; T E Bunton; L M Resar
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

7.  Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias.

Authors:  S Scala; G Portella; M Fedele; G Chiappetta; A Fusco
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

8.  Relationship between matrix metalloproteinase 2 and lung cancer progression.

Authors:  Chun-Bao Guo; Shan Wang; Chun Deng; Dian-Liang Zhang; Fu-Ling Wang; Xian-Qing Jin
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis.

Authors:  Abeba Tesfaye; Francescopaolo Di Cello; Joelle Hillion; Brigitte M Ronnett; Ossama Elbahloul; Raheela Ashfaq; Surajit Dhara; Edward Prochownik; Kathryn Tworkoski; Raymond Reeves; Richard Roden; Lora Hedrick Ellenson; David L Huso; Linda M S Resar
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

10.  Increased expression of high mobility group A proteins in lung cancer.

Authors:  V K Sarhadi; H Wikman; K Salmenkivi; E Kuosma; T Sioris; J Salo; A Karjalainen; S Knuutila; S Anttila
Journal:  J Pathol       Date:  2006-06       Impact factor: 7.996

View more
  44 in total

1.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 2.  The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

Authors:  Tait H Huso; Linda M S Resar
Journal:  Expert Opin Ther Targets       Date:  2014-03-31       Impact factor: 6.902

3.  Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies.

Authors:  Michelle H Townsend; Abigail M Felsted; Zac E Ence; Stephen R Piccolo; Richard A Robison; Kim L O'Neill
Journal:  Mol Cell Oncol       Date:  2019-02-26

4.  AKNA: another AT-hook transcription factor "hooking-up" with inflammation.

Authors:  Alison R Moliterno; Linda M S Resar
Journal:  Cell Res       Date:  2011-06-14       Impact factor: 25.617

5.  Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.

Authors:  Dwella M Nelson; Biju Joseph; Joelle Hillion; Jodi Segal; Judith E Karp; Linda M S Resar
Journal:  Leuk Lymphoma       Date:  2011-07-05

6.  Hitting the bull's eye: targeting HMGA1 in cancer stem cells.

Authors:  Breann L Yanagisawa; Linda M S Resar
Journal:  Expert Rev Anticancer Ther       Date:  2014-01       Impact factor: 4.512

Review 7.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

8.  Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Authors:  Judith E Karp; B Douglas Smith; Linda S Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark J Levis; Steven D Gore; Biju Joseph; Hetty Carraway; Michael A McDevitt; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; Michelle A Rudek
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

9.  High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells.

Authors:  Yunzhi Zhang; Teng Ma; Shuping Yang; Mingying Xia; Jing Xu; Haijia An; Yajun Yang; Shilin Li
Journal:  Mol Cell Biochem       Date:  2011-06-09       Impact factor: 3.396

10.  Knockdown of HMGA1 inhibits human breast cancer cell growth and metastasis in immunodeficient mice.

Authors:  Francescopaolo Di Cello; James Shin; Kirsten Harbom; Cory Brayton
Journal:  Biochem Biophys Res Commun       Date:  2013-03-29       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.